The association between diabetes mellitus control and advanced anti-rheumatic treatment, among rheumatoid arthritis patients: A nation-wide based, retrospective, cohort study
Main finding · b/tsDMARD initiationResult — go to the resultOdds ratio 0.87 95% CI 0.60–1.24Authors' conclusion
RA patients with UMDM, as compared with MDM, do not have higher odds of being prescribed b/tsDMARDs within the first two years after RA diagnosis.
Study context
- Population
- Rheumatoid Arthritis (RA) patients with diabetes mellitus (≥2 recorded RA diagnoses and Rheumatoid Factor (RF) or anti-CCP positive, or csDMARD purchase 1 year before 2nd RA diagnosis), nation-wideselected from 3977 RA patients
- Participants
- 400 vs 800
- Exposure
- Unmanaged Diabetes Mellitus (DM) vs managed DM in RA
- Unmanaged DM (UMDM)n = 400
- Managed DM (MDM)n = 800reference
- Outcome
- Proportion of patients prescribed a b/tsDMARD
- Follow-up
- Within the first two years after the index date
Methodological detailspopulation-based, propensity score matching (Gradient Boosting Classifier)
- Population-based
- Propensity score matching (Gradient Boosting Classifier)
Main finding
b/tsDMARD initiation · within two years from the index date
Odds ratio
0.87
95% CI 0.60–1.24
P = 0.49
By group
UMDMvs MDM
OR 0.87 (95% CI 0.60–1.24); P = 0.49
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
Mean number of b/tsDMARD switches · 2 and 5 years
- Not statistically significant between groups
Original publication
The association between diabetes mellitus control and advanced anti-rheumatic treatment, among rheumatoid arthritis patients: A nation-wide based, retrospective, cohort study. Joint Bone Spine. Published 15 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →